Share Prices & Company Research

Market News

19 Sep 2018 | 09:04

Alliance Pharma profits weighed down by higher costs

Alliance Pharma reported Wednesday a marginal increase in first-half profit amid higher costs related to acquisition of Vamousse and continued investment in the company's International Star Brands.

For the six months ended 30 June, profit before tax was up 2.0% to £12.1m, and revenues rose 10% to £54.5m.

Like-for-like revenues, excluding acquisitions, was up 3%, but they were higher on a constant currency basis at 4%.

The company said its International Star brands continued to deliver strong performance, led by Kelo-cote.

The company expected revenues and underlying profit before tax for the current financial year would be in line with its expectations as the second half of the year had started well.

The company said the UK launch of Xonvea, used to treat nausea and vomiting of pregnancy, was slated for the fourth quarter of 2018. 'We continue to evaluate bolt-on acquisitions with the objective of further driving our growth,' Alliance Pharma said.

At 9:04am: (LON:APH) Alliance Pharma PLC share price was -1.9p at 89.1p

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.